Lao PDR Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Lao PDR
2. Grant number: 1922-LAO-13b-X / 19-LAO-08b-Y
3. Date of Decision Letter: 3 April 2018
4. Date of the Partnership Framework Agreement: 7 June 2013
5. Programme title: New Vaccine Support (NVS), Rotavirus Routine
6. Vaccine type: Rotavirus
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose schedule
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)

<table>
<thead>
<tr>
<th>Year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Budget (US$)</td>
<td>394,500</td>
<td>583,500</td>
<td>356,000</td>
<td>192,000</td>
<td>1,526,000</td>
</tr>
</tbody>
</table>
10. Vaccine introduction grant (in US$): 115,575.60. Payable up to six months before vaccine introduction.
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Rotavirus vaccines doses</td>
<td>189,000</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>394,500</td>
</tr>
</tbody>
</table>
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.
13. Self-procurement: Not applicable

---

1 This is the entire duration of the Programme.
2 This is the total amount endorsed by Gavi for the entire duration of the Programme.
3 This is the amount that Gavi has approved.

According to the co-financing policy, the Country falls within the group accelerated transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>22,500</td>
<td>132,000</td>
<td>198,000</td>
<td>280,500</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>43,833</td>
<td>264,986</td>
<td>397,610</td>
<td>562,715</td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>45,500</td>
<td>274,000</td>
<td>411,000</td>
<td>581,500</td>
</tr>
</tbody>
</table>

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Not applicable

Reports and other information

To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.

Due dates

May

To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,

Barry Greene
Managing Director
Finance & Operations
The GAVI Alliance

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
3 April 2018